$383,462,829
to FRED HUTCHINSON CANCER CENTER
LEADERSHIP FOR HIV/AIDS CLINICAL TRIALS NETWORKS; HIV VACCINE TRIALS NETWORK
Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.
What the model surfaced from this award
Funds Fred Hutchinson Cancer Center's leadership of HIV/AIDS clinical trials networks and vaccine trial coordination since 2006.
Twenty-year HIV vaccine research program represents sustained U.S. investment in one of the world's most challenging vaccine targets; critical to global pandemic preparedness.
Supports clinical research infrastructure, trial recruitment networks, and vaccine manufacturing partnerships across academic and commercial biotech sectors.
HIV vaccine development is a global race; U.S. leadership in clinical trial networks and vaccine efficacy research maintains competitive advantage in infectious-disease countermeasures.
Generated by award_classification v2.1.0 via claude-haiku-4-5-20251001 on 2026-05-22. Cost: $0.002985.
- 2026-06-05LEADERSHIP GROUP FOR A GLOBAL HIV VACCINE CLINICAL TRIALS NETWORK$1.1B
- 2026-05-21HVTN LABORATORY PROGRAM$443.7M
- 2026-04-06CANCER CENTER SUPPORT GRANT (COMPREHENSIVE)$221.9M
- 2026-04-20EARLY DETECTION RESEARCH NETWORK: DATA MANAGEMENT AND COORDINATING CENTER$67.7M
- 2026-04-27IGF::OT::IGF CORE INFRASTRUCTURE SUPPORT FOR SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER)$38.3M
- USAspending.gov — all awards for this UEI →
- SAM.gov entity registration →
- Award record ingested from usaspending. Source identifier ASST_NON_UM1AI068635_075.
The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.